We are combining new, translatable multimodal platforms for cancer diagnostics with state-of-the-art imaging tools (PET, optical) for image-guided surgery/interventions, as well as non-surgical applications.
We are exploring a range of potential applications of nanotechnology within the context of cancer diagnosis and staging.
Novel Particle Probe Development
We are developing, characterizing, and optimizing the use of multimodal silica particle platforms for the detection and localization of primary tumors and metastatic disease spread in small and large animal models. These particles are cancer selective, with ligands (i.e., peptides, antibodies) attached to their surface that specifically target cancer cells. For surgical applications, we are implementing these platforms in tandem with state-of-the-art hand-held optical and PET detection devices (see below). We are also exploring correlative cancer biology at the cellular and molecular levels in clinically relevant tumor models.
- Sentinel Lymph Node (SLN) Mapping
We are performing mapping studies in spontaneous metastatic melanoma miniswine models to enhance detection of nodal metastases, stage tumors, and sensitively assess relative disease burden.
- Tumor Cell Binding and Uptake
We are conducting studies to investigate the influence of particle size and surface composition on internalization, modulation of signaling pathways, and biological processes such as cell migration and proliferation.
We are using a fluorescence camera system designed by ArteMIS Molecular Imaging BV to perform real-time optical imaging during both open and minimally invasive surgical procedures. We are testing the device in large animal models of melanoma to detect metastatic disease following administration of near-infrared dye-containing probes.
We are also developing an approach that combines fluorescence imaging and reflectance confocal microscopy in conjunction with new optical probes for imaging skin lesions and other superficial lesions along mucosal surfaces.